Rhythm

Esperto medical logo

Esperto Medical Awarded Grant by the Translational Research Institute for Space Health (TRISH) to Advance Noninvasive Monitoring Technology for Spaceflight

Esperto Medical’s Resonance Sonomanometry™ technology will be developed to enable continuous, calibration-free cardiovascular monitoring for terrestrial environments and spaceflight. FULLERTON, Calif., Nov. 6, 2026 /PRNewswire/ — Esperto Medical, Inc., a healthtech startup specializing…

Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology

Collaboration brings together Canon’s Alphenix interventional fluoroscopy system and Stereotaxis’ GenesisX robotic technologyTechnologies will be presented at TCT 2026 in the Canon booth TUSTIN, Calif. and ST. LOUIS, Oct. 30, 2026 (GLOBE NEWSWIRE) — Canon Medical Systems USA, a leader in innovative diagnostic imaging solutions, and Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced a technology compatibility and commercial collaboration to pair Canon Medical’s Alphenix interventional imaging platform with Stereotaxis’ GenesisX Robotic Magnetic Navigation system. Canon and Stereotaxis are collaborating to offer their respective systems in a compatible fashion alongside each other. Canon Medical’s Alphenix platform provides advanced imaging, visualization, dose-management and workflow capabilities for interventional cardiology, with flexible configurations designed to support complex procedures. GenesisX enables precise robotic navigation of interventional catheters, with a semi-mobile architecture designed to facilitate adoption broadly within existing catheterization labs without any construction. The combination of these two advanced technologies aims to expand access to next-generation robotic electrophysiology technology. The collaboration will enable the companies to enhance customer knowledge regarding their respective technologies, providing healthcare organizations greater flexibility when planning advanced robotic electrophysiology labs. The companies will further explore opportunities for Alphenix and GenesisX to improve workflow and introduce advanced capabilities in electrophysiology. Such efforts may apply beyond electrophysiology to support the advancement of robotic technology in interventional cardiology and neurointerventional procedures. “As electrophysiology continues to evolve, customers need the flexibility to build advanced labs around the technologies and workflows that best meet their needs,” said Tsuneo “Neo” Imai, President & CEO of Canon Medical Systems USA. “Our collaboration with Stereotaxis reinforces Canon Medical’s commitment to customer choice and creates an exciting opportunity to bring Alphenix imaging together with Robotic Magnetic Navigation.” “We are delighted to collaborate with Canon Medical to bring together two complementary technologies for the modern EP lab,” said David Fischel, Chairman and CEO of Stereotaxis. “More tightly coordinating the delivery of advanced interventional imaging and robotic technologies offers hospitals an exciting approach to building their robotic electrophysiology programs.” About Canon Medical Systems USA, Inc.Canon Medical Systems USA, Inc. markets, sells, distributes and services radiology and cardiovascular systems, including CT, MR, molecular imaging, ultrasound, X-ray, and interventional X-ray equipment. For more information, visit Canon Medical Systems’ website: https://us.medical.canon/ About Canon Medical GroupCanon Medical Group provides a comprehensive range of medical imaging solutions, including CT, diagnostic and interventional X-ray, MRI, ultrasound, service solutions, and advanced Healthcare IT. In line with Canon Medical Group’s continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to equip healthcare professionals with innovative solutions that enhance clinical performance, safety, comfort, and outcomes—helping deliver better health opportunities for patients worldwide. We invest in research and product development that directly addresses the real clinical, operational, and business needs of our customers. By improving accessibility, enabling cross-platform integration, and supporting patient-centered care pathways, we aim to deliver solutions that are both meaningful and impactful. Working hand in hand with our medical, academic, and research partners, we build relationships founded on transparency, trust, and respect. Together, we strive to create industry-leading innovations that improve patient outcomes and enrich quality of life for communities around the world. https://global.medical.canon/ About StereotaxisStereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com. Cautionary Note Regarding Forward-Looking StatementsThis press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, our overall liquidity and our ability to fund operations, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, our ability to manage and integrate recent acquisitions, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release. Stereotaxis Contacts:David L. FischelChairman and Chief Executive OfficerKimberly PeeryChief Financial Officer314-678-6100Investors@Stereotaxis.comCanon Medical Systems USA Contacts:Olivia DuarteDirector of Corporate Communications(800) 421-1968

Monebo

Monebo and Innolitics Secure FDA 510(k) Clearance for a Cross-Platform ECG Arrhythmia Analysis Library

AUSTIN, Texas–(BUSINESS WIRE)–Monebo Technologies, Inc. and Innolitics today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Kinetic Software Library (K260640), Monebo’s ECG analysis library for medical device manufacturers. The Kinetic Software Library provides ECG signal processing and analysis, including QRS detection, ectopic beat detection, QRS feature extraction, heart rate measurement and rhythm analysis. It is intended for use by qualified med

CorWave Completes Enrollment in Feasibility Study and Presents First Clinical Data on Adaptive Support with its Wave Membrane LVAD

CLICHY, France–(BUSINESS WIRE)–CorWave SA, a clinical-stage medical technology company pioneering innovative cardiac assist devices, announces the completion of enrollment in its feasibility study of the CorWave Left Ventricular Assist System (LVAS). The company also presented the first clinical data on the device’s adaptive control algorithm at the 18th Branislav ‘BRANO’ Radovancevic Heart Failure Forum, held jointly with the 19th Innovations and New Treatment Strategies in Heart Failure sym

Stereotaxis Announces First Robotic Magnetic Navigation System in Latvia

Pauls Stradiņš Clinical University Hospital installs Genesis Robotic Magnetic Navigation System, establishing the first robotic program for the treatment of cardiac arrhythmia in LatviaFirst procedures successfully treated patients with a broad range of arrhythmia ST. LOUIS, Oct. 22, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Pauls Stradiņš Clinical University Hospital in Riga, Latvia, has established the first robotic center for the treatment of cardiac arrhythmias in Latvia and has successfully treated initial patients with the Genesis Robotic Magnetic Navigation System. “The introduction of the advanced Genesis technology at Pauls Stradiņš Clinical University Hospital reflects the hospital’s long-term commitment to developing highly specialized, modern, and patient safety focused healthcare services,” said Prof. Andrejs Ērglis, Head of the Latvian Cardiology Center at Stradiņš Hospital and Professor of Medicine at the University of Latvia. “We are proud to make this technology available to the benefit of arrhythmia patients, allowing all patients to benefit from the precision, controlled catheter movement, and safety of robotics. We particularly see value in our robotic program expanding the potential to treat complex cardiac arrhythmia.” Pauls Stradiņš Clinical University Hospital is Latvia’s premier hospital, academic and research center, with a strong reputation in cardiology excellence. The Genesis Robotic Magnetic Navigation system introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmia may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest. “We are delighted to establish this new robotic electrophysiology center of excellence with Pauls Stradiņš Clinical University Hospital,” said David Fischel, Chairman and CEO of Stereotaxis. “We look forward to collaborating with the hospital and cardiology team to advance patient care in Latvia and advance clinical science that will have a global impact.” About StereotaxisStereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com. Cautionary Note Regarding Forward-Looking StatementsThis press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, our overall liquidity and our ability to fund operations, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, our ability to manage and integrate recent acquisitions, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release. Stereotaxis Contacts: David L. FischelChairman and Chief Executive Officer Kimberly PeeryChief Financial Officer 314-678-6100Investors@Stereotaxis.com

Medtronic logo

Medtronic announces positive results from real-world registries for the Sphere-9™ catheter and PulseSelect™ PFA System at APHRS 2026

Global APEX and REAL PULSE Registry analyses report strong safety and procedural outcomes across atrial and ventricular arrhythmias Medtronic continues to strengthen its position in cardiac ablation, building on a legacy of innovation in electrophysiology GALWAY, Ireland, Oct. 22, 2026…